The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS
Open accessAbstract
BACKGROUND: The echinoderm microtubule‐associated protein‐like 4‐anaplastic lymphoma kinase ( EML4‐ALK ) fusion gene resulting from the chromosome inversion inv(2)(p21;p23) recently was identified in nonsmall cell lung cancer (NSCLC). The authors of this study investigated the frequency, genetic and clinicopathologic profiles of EML4‐ALK in Chinese patients with NSCLC. METHODS: EML4‐ALK was investigated in 266 resected primary NSCLC, including adenocarcinomas (AD), lymphoepithelioma‐like carcinomas, squamous cell carcinomas, mucoepidermoid carcinomas, and adenosquamous carcinomas, by reverse transcriptase‐polymerase chain reaction and was verified by sequencing. EML4‐ALK protein expression was studied by immunohistochemistry. RESULTS: Thirteen tumors (4.9%) had EML4‐ALK comprising 4 fusion transcript variants with fusion of the variable segments from 5′ EML4 to 3′ ALK and with preservation of the ALK kinase domain. The most common variant consisted of 8 tumors with variant 3 that involved EML4 exon 6. The others included 2 tumors with variant 1 (exon 13), 2 tumors with variant 2 (exon 20), and 1 tumor with the novel variant 5 (exon 18). There were 11 ADs and 2 unusual carcinomas with mixed squamous and glandular components. Immunohistochemistry demonstrated diffuse ALK fusion proteins in the tumor cell cytoplasm. EML4‐ALK was associated with nonsmokers ( P = .009). Tumors with the fusion gene had the wild‐type epidermal growth factor receptor ( EGFR ) ( P = .001) and v‐Ki‐ ras 2/Kirsten rat sarcoma viral oncogene homolog ( KRAS ) genes. Patients who had EML4‐ALK ‐positive AD had a younger median age ( P = .018) compared with patients who did not have the fusion gene. CONCLUSIONS: The EML4‐ALK fusion gene was present in various histologic types of NSCLC. It occurred in mutual exclusion to EGFR and KRAS mutations and was associated with nonsmokers. The authors concluded that EML4‐ALK may be useful for predicting the potential response to ALK inhibitors as a therapeutic option for patients with lung cancer. Cancer 2009. © 2009 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
The impact of translocations and gene fusions on cancer causation
Mitelman, F., Johansson, B., & Mertens, F. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2091 · Cited by 1,400
EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
Koivunen, J. P., Mermel, C., Zejnullahu, K., Murphy, C., Lifshits, E., Holmes, A. J., Choi, H. G., Kim, J., Chiang, D., Thomas, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0168 · Cited by 993
Iwahara, T., Fujimoto, J., Wen, D., Cupples, R., Bucay, N., Arakawa, T., Mori, S., Ratzkin, B., & Yamamoto, T. (1997) · Oncogene · doi:10.1038/sj.onc.1200849 · Cited by 726
TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors
Lawrence, B., Perez-Atayde, A., Hibbard, M. K., Rubin, B. P., Dal Cin, P., Pinkus, J. L., Pinkus, G. S., Xiao, S., Yi, E. S., Fletcher, C. D. M., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64550-6 · Cited by 714
EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers
Inamura, K., Takeuchi, K., Togashi, Y., Nomura, K., Ninomiya, H., Okui, M., Satoh, Y., Okumura, S., Nakagawa, K., Soda, M., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31815e8b60 · Cited by 467
Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non–Small Cell Lung Cancer
Choi, Y. L., Takeuchi, K., Soda, M., Inamura, K., Togashi, Y., Hatano, S., Enomoto, M., Hamada, T., Haruta, H., Watanabe, H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6158 · Cited by 438
Tam, I. Y. S., Chung, L. P., Suen, W. S., Wang, E., Wong, M. C. M., Ho, K. K., Lam, W. K., Chiu, S. W., Girard, L., Minna, J. D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1981 · Cited by 400
Self-citationMcDermott, U., Iafrate, A. J., Gray, N. S., Shioda, T., Classon, M., Maheswaran, S., Zhou, W., Choi, H. G., Smith, S. L., Dowell, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6186 · Cited by 399
A Translational View of the Molecular Pathogenesis of Lung Cancer
Sato, M., Shames, D. S., Gazdar, A. F., & Minna, J. D. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000263718.69320.4c · Cited by 297
EML4-ALK Fusion Lung Cancer: A Rare Acquired Event
Perner, S., Wagner, P. L., Demichelis, F., Mehra, R., LaFargue, C. J., Moss, B. J., Arbogast, S., Soltermann, A., Weder, W., Giordano, T. J., et al. (2008) · Neoplasia · doi:10.1593/neo.07878 · Cited by 249
Anaplastic lymphoma kinase proteins in growth control and cancer
Pulford, K., Morris, S. W., & Turturro, F. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.10472 · Cited by 227
Causes of oncogenic chromosomal translocation
Aplan, P. D. (2006) · Trends in Genetics · doi:10.1016/j.tig.2005.10.002 · Cited by 196
Shinmura, K., Kageyama, S., Tao, H., Bunai, T., Suzuki, M., Kamo, T., Takamochi, K., Suzuki, K., Tanahashi, M., Niwa, H., et al. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.12.013 · Cited by 164
Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines
Dirks, W. G., Fähnrich, S., Lis, Y., Becker, E., MacLeod, R. A. F., & Drexler, H. G. (2002) · International Journal of Cancer · doi:10.1002/ijc.10435 · Cited by 125
Human EML4, a novel member of the EMAP family, is essential for microtubule formation
Pollmann, M., Parwaresch, R. M., Adam‐Klages, S., Kruse, M., Buck, F., & Heidebrecht, H.-J. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.06.035 · Cited by 92
EML4–ALK fusion transcript is not found in gastrointestinal and breast cancers
Fukuyoshi, Y., Inoue, H., Kita, Y., Utsunomiya, T., Ishida, T., & Mori, M. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604341 · Cited by 63
Houtman, S. H., Rutteman, M., Zeeuw, C. I. D., & French, P. J. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.11.015 · Cited by 61
Lam, D. C.-L., Girard, L., Suen, W., Chung, L., Tin, V. P., Lam, W.-K., Minna, J. D., & Wong, M. P. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)31624-5 · Cited by 41
Self-citationEvidence of recurrent gene fusions in common epithelial tumors
Kumar‐Sinha, C., Tomlins, S. A., & Chinnaiyan, A. M. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.09.005 · Cited by 32
Cited by
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,792
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,870
Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495
Metadata
- Authors
- Wong, D. W., Leung, E. L., So, K. K., Tam, I. Y., Sihoe, A. D., Cheng, L., Ho, K., Au, J. S., Chung, L., Pik Wong, M., & University of Hong Kong Lung Cancer Study Group
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2009-04-06
- Volume
- 115
- Issue
- 8
- Pages
- 1723-1733
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2031494655
- Cited by
- 719
- References
- 23
- FWCI
- 50.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.